Brief: Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync

Nexalin Technology

03/12/2025 13:03

Dec 3 (Reuters) - Nexalin Technology Inc NXL.O:

NEXALIN TECHNOLOGY COMPLETES FDA Q-SUBMISSION MEETING FOR GEN-2 SYNC™ NEUROSTIMULATION CONSOLE IN ALZHEIMER’S DISEASE PROGRAM

NEXALIN TECHNOLOGY INC: INTENDS TO INCORPORATE FDA'S FEEDBACK FROM Q-SUB MEETING INTO ITS FINAL PILOT STUDY PROTOCOL

Source text: ID:nGNXbl61b0

Further company coverage: NXL.O

 ((Reuters.Briefs@thomsonreuters.com;))